Clinical Development, In-Vivo and Life Science

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo

In-Vivo Gene Editing Trials Gene

Forbion European Acquisition and enGene sign merger deal

Pharmaceutical Technology

MAY 18, 2023

Other investors include Investissement Québec, Omega Funds, Cowen Healthcare Investments, CTI Life Sciences Fund III, Northleaf Capital Partners, BVF Partners and Vivo Capital. The therapy is currently being developed to treat Bacillus Calmette-Guérin (BCG)-resistant NMIBC with carcinoma-in-situ.

Gene Therapy

Gene Therapy Gene In-Vivo Life Science

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

JANUARY 6, 2021

SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. Further research on and development of the compound is ongoing with the objective of completing preclinical studies. About Standigm. Standigm is an AI-driven drug discovery company.

FDA Approval

FDA Approval Life Science Drugs In-Vivo

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science

Life Science Antibody In-Vivo In-Vitro

Identify and Validate Innovative Peptides for the Treatment of Obesity

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. population will have obesity. About Boehringer Ingelheim.

In-Vivo

In-Vivo Contract Manufacturing Bioinformatics Clinical Development

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — IO Biotech , a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. COPENHAGEN, Denmark , Jan.

In-Vivo

In-Vivo Antibody Vaccination Vaccine

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

XTalks

APRIL 24, 2023

Melanie Blank, clinical team leader for General Medicine Branch 1 at the US Food and Drug Administration’s (FDA) Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), the agency is seeing one or two new applications coming in every week for new gene therapies for different diseases.

Gene Therapy

Gene Therapy Gene Trials Clinical Trials

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo

In-Vivo In-Vitro Antibody Development

Fortis Life Sciences leads the way in custom antibody discovery

Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Fortis Life Sciences offers custom antibody discovery and manufacturing services for antibodies and single-domain antibodies, supporting the drug discovery market.

Life Science

Life Science Antibody Manufacturing In-Vivo

Strategies to Successfully Manage Complex Cell Therapy Clinical Trials

XTalks

FEBRUARY 10, 2023

According to a recent review published in Nature , as of April 2022 almost 1,800 active cell therapy clinical trials were listed in ClinicalTrials.gov, a 33 percent increase from 2021. The rapidly expanding landscape of cell therapy trials has put an operational strain on many clinical sites due to limited resources and infrastructure. “In

Clinical Trials

Clinical Trials Clinical Trials Trials Gene Therapy

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein

Protein Antibody Engineer Scientist

The evolution of assays for immuno-oncology research

Drug Discovery World

FEBRUARY 15, 2023

Further studies elucidating the role of tumour microenvironment and its immunosuppressive elements including tumour associated macrophages have shown encouraging results in improving the efficacy of IO therapies. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research

Research In-Vitro In-Vivo Development

Reflecting on PEGS Europe 2023

Drug Discovery World

NOVEMBER 30, 2023

The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023.

Antibody

Antibody Protein Engineer In-Vivo

BioSpace Movers & Shakers, Oct. 16

The Pharma Data

OCTOBER 15, 2020

Assembly Biosciences – Former Gilead Sciences CEO John McHutchison, currently president and CEO of Assembly, was named the recipient of the Advance 2020 Global Impact award. The award honors McHutchison’s work in developing life-changing and curative therapies for patients with the hepatitis C virus. marketing and diagnostics.

In-Vivo

In-Vivo Business Development Manufacturing Development

Clinical Research Informer

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

Forbion European Acquisition and enGene sign merger deal

Trending Sources

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

Identify and Validate Innovative Peptides for the Treatment of Obesity

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Fortis Life Sciences leads the way in custom antibody discovery

Strategies to Successfully Manage Complex Cell Therapy Clinical Trials

What to expect from PEGS Europe 2023: Day 3

The evolution of assays for immuno-oncology research

Reflecting on PEGS Europe 2023

BioSpace Movers & Shakers, Oct. 16

Stay Connected